IGF2BP2 and metabolic dysfunction-associated steatotic liver disease: While IGF2BP2 has been reported to drive the progression of NASH through elevating hepatic iron deposition and increasing production of hepatic-free cholesterol.73,74 In contrast, global IGF2BP2 deficiency prevents mice from NAFLD by causing resistance to obesity and fatty liver, whereas hepatocyte-specific deletion of IGF2BP2 promotes moderate diet-induced fatty liver through impairing FA oxidation by increasing mRNA degradation of PPARα and carnitine palmitoyltransferase 1A which were supposed to be stabilized and bound by IGF2BP2.75